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Abstract
A number of genetic variants have been linked to increased risk of breast cancer. Little is, however, known about the
prognostic significance of hereditary factors. Here, we investigated the frequency and prognostic significance of two ERBB4
promoter region variants, 2782G.T (rs62626348) and 2815A.T (rs62626347), in a cohort of 1010 breast cancer patients.
The frequency of nine previously described somatic ERBB4 kinase domain mutations was also analyzed. Clinical material
used in the study consisted of samples from the phase III, adjuvant, FinHer breast cancer trial involving 1010 women. Tumor
DNA samples were genotyped for ERBB4 variants and somatic mutations using matrix-assisted laser desorption ionization/
time of flight mass spectrometry. Paraffin-embedded tumor sections from all patients were immunohistochemically stained
for ErbB4 expression. Association of ERBB4 genotype to distant disease-free survival (DDFS) was assessed using Kaplan-Meier
and Cox regression analyses. Genotyping was successful for 91–93% of the 1010 samples. Frequencies observed for the
ERBB4 variants were 2.5% and 1.3% for 2782G.T and 2815A.T, respectively. Variant 2815A.T was significantly
associated with poor survival (HR = 2.86 [95% CI 1.15–6.67], P= 0.017). In contrast, variant 2782G.T was associated with
well-differentiated cancer (P= 0.019). Two (0.2%) ERBB4 kinase domain mutations were found, both of which have
previously been shown to be functional and promote cancer cell growth in vitro. These data present the germ-line ERBB4
variant 2815A.T as a novel prognostic marker in high-risk early breast cancer and indicate the presence of rare but
potentially oncogenic somatic ERBB4 mutations in breast cancer.
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Introduction
Breast cancer is the most frequently diagnosed cancer and the
leading cause of death due to a malignancy among women [1].
Hereditary genetic factors are thought to account for approxi-
mately 5 to 10% of breast cancers due to germ-line variants in
genes that increase the risk for breast cancer, such as BRCA1 and
BRCA2 [2]. Although a number of germ-line variants have been
linked to increased risk of breast cancer [2], less is known about
the prognostic significance of hereditary variants.
ErbB4 is a member of the EGF receptor (EGFR) subfamily of
receptor tyrosine kinases including EGFR (ErbB1), ErbB2 (HER2,
neu), ErbB3 (HER3), and ErbB4 (HER4) [3]. Despite of active
research on ErbB4 biology in normal mammary tissue and breast
cancer, significance of ErbB4 for breast carcinogenesis is still
poorly understood. ErbB4 expression is typically associated with
ER- and PR-positivity, ErbB2 receptor-negativity, well-differenti-
ated phenotype and favorable outcome [4–7]. On the other hand,
ErbB4 overexpression has been associated with shorter relapse-
free survival in early, node-negative tumors [8] and with decreased
survival in patients with node-positive tumors [9]. Treatment with
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ErbB4-targeted monoclonal antibody suppresses the growth of
breast cancer cells [10], suggesting a possible oncogenic role of
ErbB4 in breast cancer.
The role of ERBB4 gene variation in breast cancer has been
less extensively studied. We have previously shown that a single
nucleotide polymorphism (SNP) 2782 G.T in the promoter
region of ERBB4 gene is a novel risk variant for breast cancer in
German population [11]. Two recent studies have also discovered
variants of ERBB4 gene that are associated with increased risk for
breast cancer. ERBB4 SNP rs13393577 was implicated as a new
risk variant in a genome-wide association study (GWAS)
conducted in Korean population [12], and three ERBB4 risk
variants (rs905883, rs7564590, and rs7558615) were identified in a
family-based GWAS in patients of the Framingham heart study
[13]. However, no studies have addressed the possible prognostic
or predictive value of ERBB4 variants.
According to the Catalogue Of Somatic Mutations In Cancer
(COSMIC), somatic ERBB4 mutations in breast cancer are rare,
as only 1.4% of breast cancers harbor ERBB4 missense mutations
(17 out of 1200 patients) [14]. Although the functional
consequences of ERBB4 breast cancer mutations have not been
studied, one ERBB4 kinase domain mutation (E872K) initially
found in breast cancer [15] has later been shown to be functionally
active in metastatic melanoma [16].
Here, we analyzed the frequencies and prognostic value of two
ERBB4 promoter variants, 2782G.T and 2815A.T in a large
phase III clinical trial data set of high-risk early breast cancer
patients (n = 1010). Frequency of nine specific ERBB4 kinase
domain mutations [15] was also analyzed. The results indicate that
the ERBB4 variant 2815A.T was significantly associated with
poor distant disease-free survival, indicating for the first time a
possible prognostic significance for a genetic variant of ERBB4 in
cancer. The frequency of the analyzed ERBB4 kinase domain
mutations was low (0.2%). However, both somatic mutations had
previously been shown to be functional and promote cancer cell
growth in vitro [16,17], suggesting a presence of rare but
oncogenic ERBB4 mutations in breast cancer.
Materials and Methods
Patient DNA and tumor tissue samples
Study material consisted of DNA and formalin-fixed, paraffin-
embedded tissue samples from primary tumors of 1010 women
with high-risk early breast cancer who participated in the adjuvant
phase III FinHer trial (International Standard Ran- domised
Controlled Trial number, ISRCTN76560285) [18]. The key
inclusion criteria in the FinHer trial were histologically confirmed
invasive breast cancer, age 65 or less, macroscopically complete
surgery for breast cancer, presence of at least one positive axillary
lymph node or a node-negative breast cancer with tumor diameter
at least 20 mm and a negative immunostaining for progesterone
steroid hormone receptors. Patients with distant metastases at the
time of randomization were excluded. Most (89%) of the study
patients had axillary lymph node-positive cancer [18]. All patients
were randomly assigned to receive three cycles of vinorelbine or
docetaxel together with fluorouracil, epirubicin and cyclophos-
phamide. Patients with ERBB2-positive tumors (n = 232) were
also assigned to receive or not to receive adjuvant trastuzumab.
The patients signed an informed consent for use of breast tumor
tissue samples for research purposes prior to entry to the clinical
trial. The protocol of the present study was approved by an Ethics
Committee of the Helsinki University Central Hospital.
Analysis of ERBB4 variants and somatic mutations
Two ERBB4 germline single nucleotide variants, 2782G.T
and 2815A.T [11], and nine previously described somatic
ERBB4 mutations [15] were genotyped to establish allele and
genotype frequencies in the FinHer cohort. Genotyping was
carried out with matrix-assisted laser desorption ionization/time of
flight mass spectrometry using SpectroCHIP microarray and
Bruker Autoflex (Sequenom) as well as MTP Anchor Chip 400/
384 TF and Bruker Ultraflex (Bruker Daltonics) [11]. The ERBB4
variant analyses were conducted using tumor DNA, as no DNA
from non-neoplastic tissue was available. However, when the
variants were initially identified from tumor DNA of colorectal
cancer patients, the variants were confirmed to be germ-line in all
cases [11].
ErbB4 immunohistochemistry
Paraffin-embedded tumor sections were stained for ErbB4 using
HFR-1 monoclonal antibody (2 mg/ml; Abcam), anti-mouse
Envision+ System HRP secondary antibody (code K4001; Dako
Cytomation), and DAB+ (code K3468; Dako Cytomation)
peroxidase substrate. All incubations were carried out in room
temperature, and all steps were followed by a rinsing step in
50 mM Tris-HCl pH 7.6 containing 0.05% Tween-20. Sections
were counterstained with hematoxylin. ErbB4-positive breast
cancer control sections were used as positive controls for each
staining series.
Statistical analyses
Frequency tables were analyzed using the chi-squared test or
Fisher’s exact test. Survival analyses were carried out with Kaplan-
Meier statistics, and survival between groups was compared with
the log-rank test. The hazard ratio was computed using a
univariable Cox model. Distant disease-free survival was calculat-
ed from the date of randomization to the date of detection of
distant recurrence of breast cancer or to the date of death
whenever death preceded distant recurrence, censoring patients
who were alive without distant recurrence on the date of last
follow-up [19]. All P-values are 2-tailed.
Results
Frequencies of ERBB4 promoter region variants 2782G.
T and 2815A.T
To investigate the prevalence of two ERBB4 promoter region
SNPs, 2782G.T and 2815A.T, tumor DNA samples from
1010 women with high-risk early breast cancer were analyzed.
Successful genotype was obtained from 936 (93%) and 932 (92%)
patient samples for ERBB4 promoter positions 2782 and 2815,
respectively. From these patients, 23 (2.5%) were genotyped to
harbor the ERBB4 2782G.T variant whereas 12 patients (1.3%)
harbored the 2815A.T variant. All genotypes were heterozy-
gous, with the exception of one homozygous 2782TT genotype
that was not included in the subsequent statistical analyses.
Associations of ERBB4 variants with clinicopathological
features and ErbB4 protein expression
When the ERBB4 promoter region SNP status was compared
with clinicopathological characteristics, the 2782G.T variant
was associated with well-differentiated cancer (P=0.018; Table 1).
Neither of the SNPs was significantly associated with primary
tumor diameter, axilliary nodal status, histology, tumor grade, ER
or PR expression, or ERBB2 amplification (Table 1). Sixteen
(69.6%) out of the 23 cancers with the 2782G.T variant were
ERBB4 SNP Is Associated with Poor Survival in Breast Cancer
PLOS ONE | www.plosone.org 2 July 2014 | Volume 9 | Issue 7 | e102388
ER-positive and ERBB2-negative in immunohistochemical stain-
ings (an approximation for the luminal A biological subtype) as
compared with 548 (62.8%) out of the 872 cancers that did not
harbor this variant (P=0.510; one of the seven remaining 2
782G.T cases was ER+/ERBB2+, three ER2/ERBB2+, and
three ER2/ERBB22). Nine (75.0%) of the 12 cancers with the2
815A.T variant were ER+ and ERBB22 (the remaining three
were ER–/ERBB2–) as compared with 553 (63.2%) out of the 874
cancers that did not harbor 2815A.T (P=0.551). All 8 tumors
with the 2815A.T variant stained by immunohistochemistry for
the p53 protein expression stained negative, whereas 4 (20.0%) out
of the 20 cases with the 2782G.T variant stained positively for
p53 [20].
To address whether the two SNPs regulated ErbB4 expression
levels in primary tumors, tumor sections from all the 1010 patients
were immunohistochemically stained with a monoclonal antibody
recognizing the C-terminus of ErbB4 (HFR-1). However, no
associations were found between ERBB4 SNP status and ErbB4
staining intensity (Table 1). Also, no statistically significant
associations were found when cytoplasmic and nuclear ErbB4
staining intensities were separately scored and compared with the
ERBB4 SNP status (data not shown). ErbB4 protein expression
did not correlate with patient survival (P=0.826, n = 926), but was
strongly associated with ER-positivity (P=0.003) (Supplementary
table 1).
Prognostic significance of ERBB4 variants
The prognostic significance of the ERBB4 variants was assessed
by analyzing the association of ERBB4 SNP status with distant
disease-free survival (DDFS). No association between ERBB4 2
782G.T and DDFS was found (Figure 1A). In contrast, the
ERBB4 variant 2815A.T was significantly associated with poor
prognosis (HR=2.86 [95% CI 1.15-6-67], P=0.017; Figure 1B).
Frequency of ERBB4 kinase domain mutations
The frequency of nine previously reported [15] somatic ERBB4
kinase domain mutations V721I, A773S, R782Q, G802dup,
E810K, P854Q, D861Y, E872K, and T926M, including a
mutation previously found in breast cancer (E872K), was also
analyzed from the tumor DNA samples. The different point
mutations were successfully analyzed from 91–93% of the 1010
samples. Two tumors out of all the genotyped tumors were found
to harbor ERBB4 kinase domain mutations G802dup or E872K.
Table 1. Clinicopathological features of patients harboring ERBB4 variants 2782G.T or 2815A.T.
2782 G.T 2815 A.T
GG GT AA AT
n (%) n (%) P-value n (%) n (%) P-value
Frequency 872 (98) 23 (2) 879 (99) 12 (1)
pT
#20 mm 364 (98) 9 (2) 366 (99) 5 (1)
.20 mm 508 (98) 13 (2) 0.938 512 (99) 7 (1) 0.999
pN
negative 91 (97) 3 (3) 95 (99) 1 (1)
positive 781 (98) 20 (2) 0.726 784 (99) 11 (1) .0.999
Histology
ductal 682 (97) 19 (3) 689 (99) 9 (1)
lobular/other 190 (98) 4 (2) 0.799 190 (98) 3 (2) 0.729
Grade
1 121 (94) 8 (6) 0.018 125 (98) 3 (2) 0.408
2 352 (98) 7 (2) 356 (99) 3 (1)
3 362 (98) 7 (2) 361 (98) 6 (2)
ER
- 242 (97) 7 (3) 243 (99) 3 (1)
+ 630 (98) 16 (2) 0.777 636 (99) 9 (1) .0.999
PR
- 373 (97) 10 (3) 371 (98) 6 (2)
+ 498 (97) 13 (3) 0.959 507 (99) 6 (1) 0.590
ERBB2
- 675 (97) 19 (3) 678 (77) 12 (2)
+ 197 (98) 4 (2) 0.555 201 (23) 0 (0) 0.079
ErbB4 IHC
negative 138 (96) 6 (4) 140 (97) 4 (3)
positive 697 (98) 15 (2) 0.145 701 (99) 7 (1) 0.098
doi:10.1371/journal.pone.0102388.t001
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Discussion
Clinical studies on association of ErbB4 expression with breast
cancer patient survival are contradictory [4–9,21], despite in vitro
as well as in vivo mouse xenograft data suggesting an oncogenic
role for ErbB4 in breast cancer [10,22,23]. However, the
prognostic or predictive role of germ-line or somatic ERBB4
mutations in breast cancer has not been addressed. Here we
analyzed the frequencies and prognostic significance of two
ERBB4 genetic variants, 2782G.T and 2815A.T [11] in a
cohort of 1010 patients with high-risk early breast cancer. The
frequencies of nine specific ERBB4 kinase domain mutations [15]
was also investigated.
The frequencies of the two ERBB4 variants were 2.5% (23 out
of 936 patients) and 1.3% (12 out of 932 patients) for 782G.T
and 2815A.T, respectively. In our previous study using samples
from German GENICA breast cancer colletion, the frequencies
were 5.3% and 1% for 782G.T and 2815A.T, respectively
[11]. The variant 2815A.T was significantly associated with
poor prognosis. Interestingly, the variant 2782G.T, which was
implicated as a risk factor for breast cancer in our previous study
[11], was not associated with distant disease-free survival, but with
well-differentiated cancer. These data suggest that the heterozy-
gous genotype ERBB4 2815A/T could be a prognostic marker in
high-risk early breast cancer. This is the first indication of
prognostic significance for a genetic variant of ERBB4 in cancer.
However, these findings should be confirmed in an independent
large patient cohort. The association between the ERBB4 2
815A/T polymorphism and clinical outcome serves the hypothesis
that ErbB4-targeted therapy could be beneficial for a subgroup of
breast cancer patients in the adjuvant setting.
Immunohistochemical analysis of ErbB4 protein expression
levels in the tumors demonstrated that neither of the ERBB4
variants induced significant changes in ErbB4 expression or
subcellular localization in the primary tumors. Total ErbB4
expression also did not associate with DDFS of the patients, but
correlated with ER-positivity. This is in accordance with reports
associating ErbB4 protein expression with markers of favorable
prognosis [4–7].
Our analysis of specific ERBB4 kinase domain mutations
revealed two patients harboring somatic ErbB4 mutations
G802dup and E872K, respectively. Interestingly, E872K is a
mutation initially found in breast cancer [15] that was later also
detected in melanoma [16]. The other mutation, G802dup, has
previously been reported in non-small cell lung cancer [15]. Both
mutations have been shown to be functional and promote cancer
cell/tumor growth in vitro [16,17], suggesting the presence of rare
but potentially oncogenic ERBB4 mutations in breast cancer.
Although the observed ERBB4 mutation frequency (0.2%) is low,
it corresponds to the frequency of ERBB2 kinase domain
mutations (0.5%) in the same patient cohort [24]. Rare ERBB2
kinase domain mutations have recently been suggested to serve as
predictive markers for ErbB2-targeted therapy in the absence of
ERBB2 amplification [25], indicating that rare mutations may
have clinical relevance in high-incidence cancers such as breast
cancer.
Taken together, this study presents a genetic ERBB4 variant as
a novel prognostic marker in high-risk early breast cancer and
indicates the presence of rare but potentially oncogenic ERBB4
mutations in breast cancer.
Supporting Information
Table S1 Associations of immunohistochemical ErbB4 staining
intensity with clinicopathological parameters.
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Figure 1. Prognostic associations of the ERBB4 variants. Kaplan-Meier plots of distant disease-free survival of patients harboring wild-type
ERBB4 or ERBB4 variants 2782G.T (A) or 2815A.T (B).
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